Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2015

Open Access 01-12-2015 | Erratum

Erratum: OTUB1 de-ubiquitinating enzyme promotes prostate cancer cell invasion in vitro and tumorigenesis in vivo

Authors: Diego Iglesias-Gato, Yin-Choy Chuan, Ning Jiang, Charlotte Svensson, Jing Bao, Zhiqun Shang, Indranil Paul, Lars Egevad, Benedikt M Kessler, Pernilla Wikström, Yuanjie Niu, Amilcar Flores-Morales

Published in: Molecular Cancer | Issue 1/2015

Login to get access

Excerpt

After publication of this study [1], we found that we unintentionally failed to provide the complete list of all coauthors. This error has now been corrected and the full list of authors contributing to this work is included. Authors’ contributions and Competing interests sections have been modified accordingly. …
Literature
1.
Iglesias-Gato D, Chuan YC, Jiang N, Svensson C, Bao J, Paul I, et al. OTUB1 de-ubiquitinating enzyme promotes prostate cancer cell invasion in vitro and tumorigenesis in vivo. Mol Cancer. 2015;14:8.CrossRefPubMedCentralPubMed
Metadata
Title
Erratum: OTUB1 de-ubiquitinating enzyme promotes prostate cancer cell invasion in vitro and tumorigenesis in vivo
Authors
Diego Iglesias-Gato
Yin-Choy Chuan
Ning Jiang
Charlotte Svensson
Jing Bao
Zhiqun Shang
Indranil Paul
Lars Egevad
Benedikt M Kessler
Pernilla Wikström
Yuanjie Niu
Amilcar Flores-Morales
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2015
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-015-0341-1

Other articles of this Issue 1/2015

Molecular Cancer 1/2015 Go to the issue

Research

Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL

Research

Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine

Review

The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses

Research

The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells

Research

Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model

Review

Genetic instability in the tumor microenvironment: a new look at an old neighbor
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits